Paul G Richardson MD

Hematologic Oncology

Associate Professor, Medicine, Brigham & Women's Hospital, Harvard Medical School

44 Binney St# DanaBoston, MA 02115
Phone+1 617-632-2104
Fax+1 617-632-6624

Dr. Richardson is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Richardson's full profile Already have an account?

Education & Training

UMass Chan - BaystateFellowship, Hematology and Medical Oncology, 1991 - 1994
Charing Cross and Westminister Medical SchoolClass of 1986

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2022 - Present
CT State Medical License 2022 - 2026
MA State Medical License 1993 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014
America's Top Doctors Castle Connolly, 2011-2014
Boston Magazine Castle Connolly, 2010-2013

Clinical Trials

High-dose ICE With Amifostine
COMPLETED
PHASE2
Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation
COMPLETED
PHASE2
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma
COMPLETED
PHASE1

Publications & Presentations

PubMed

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, ope...
Meletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, Monique A Hartley-Brown, Cesar Gomez
Lancet. 2026-07-18
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.
Shaji Kumar, Susanna Jacobus, Adam Cohen, Matthias Weiss, Natalie Callander
The New England Journal of Medicine. 2026-07-16
2 citations
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.
Omar Nadeem, David M Cordas Dos Santos, Sarah Nikiforow, Anna Bosch-Vilaseca, Elizabeth O'Donnell
Nature Medicine. 2026-07-01

Journal Articles

APRIL Signaling via TACI Mediates Immunosuppression by T Regulatory Cells in Multiple Myeloma: Therapeutic Implications
Kenneth C Anderson, Nikhil Munshi, Paul Richardson, Chirag Acharya, Nature
Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
How I Treat the Young Patient with Multiple Myeloma
Paul Richardson, MD, Blood

Abstracts/Posters

High-Dimensional Heterogeneity of Waldenstr_m Macroglobulinemia within Its Immune Tumor Microenvironment
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Basel...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Current Obstacles in Myeloma Management: Debating the Evidence
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 S...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Navigating Early Relapse in Multiple Myeloma: New Evidence From the 2026 ASCO and EHA CongressesAugust 24th, 2026
FDA Approves First CELMoD Agent, with Dana-Farber Helping Advance Its DevelopmentAugust 14th, 2026
ASCO 2026: Multiple Myeloma Studies Highlight Advances Across the FieldJuly 25th, 2026